Paris, 15 December 2021
In its response, Prescrire stressed the need for robust evidence before marketing authorisation is granted. Accelerated assessments should be limited to real unmet health needs, with due attention paid to whether post-marketing commitments are fulfilled. To ensure safety of supply, there is a need for diversification of supply chains and transparency over production sites and capacity.
> Click here to download Prescrire's contribution (pdf, 145 Ko)
©Prescrire December 2021
Share |
 |
 |